{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:03:04Z","timestamp":1777129384866,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010605","name":"Texas Department of Agriculture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jfma.2022.12.005","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:40:00Z","timestamp":1671608400000},"page":"540-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Taiwanese dermatological association (TDA) consensus for the management of pemphigus"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-3279","authenticated-orcid":false,"given":"Chia-Yu","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9804-3874","authenticated-orcid":false,"given":"Chih-Hung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-En","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5297-8997","authenticated-orcid":false,"given":"Yung-Tsu","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Kai","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Chou","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Che","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2022.12.005_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.7861\/clinmedicine.9-4-371","article-title":"Pemphigus: a brief review","volume":"9","author":"Groves","year":"2009","journal-title":"Clin Med"},{"key":"10.1016\/j.jfma.2022.12.005_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jdermsci.2020.08.002","article-title":"National trends in incidence, mortality, hospitalizations, and expenditures for pemphigus in Taiwan","volume":"99","author":"Chiu","year":"2020","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jfma.2022.12.005_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jfma.2022.12.005_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 guideline for diagnosis and treatment--guided by the European dermatology Forum (EDF) in cooperation with the European Academy of dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfma.2022.12.005_bib6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1590\/abd1806-4841.2019940206","article-title":"Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology","volume":"94","author":"Porro","year":"2019","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13016","article-title":"Iranian guideline for rituximab therapy in pemphigus patients","volume":"32","author":"Daneshpazhooh","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jfma.2022.12.005_bib9","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated s2k guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfma.2022.12.005_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12016-021-08882-1","article-title":"Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies","volume":"61","author":"Zhao","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jfma.2022.12.005_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2022.12.005_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1726-4901(09)70304-1","article-title":"Using desmoglein 1 and 3 enzyme-linked immunosorbent assay as an adjunct diagnostic tool for pemphigus","volume":"70","author":"Huang","year":"2007","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jfma.2022.12.005_bib13","first-page":"343","article-title":"Comparison of histopathology, immunofluorescence, and serology for the diagnosis of autoimmune bullous disorders: an update","volume":"3","author":"Seline","year":"2016","journal-title":"Glob Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the autoimmune bullous skin disorder intensity score (ABSIS) and pemphigus disease area index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1006\/jsre.2000.5909","article-title":"Percentage of burned body surface area determination in obese and nonobese patients","volume":"91","author":"Livingston","year":"2000","journal-title":"J Surg Res"},{"key":"10.1016\/j.jfma.2022.12.005_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"Hebert","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/archderm.144.5.682","article-title":"Kinetics of response to conventional treatment in patients with pemphigus vulgaris","volume":"144","author":"Czernik","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1468-3083.2011.04170.x","article-title":"Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study","volume":"26","author":"Ioannides","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfma.2022.12.005_bib19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/archderm.1996.03890360091015","article-title":"Pulse glucocorticoid therapy: the 'big shot' revisited","volume":"132","author":"Roujeau","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaad.2020.08.028","article-title":"Network meta-analysis\u2013based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus","volume":"85","author":"Lee","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2340\/00015555-1746","article-title":"First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus","volume":"94","author":"Cho","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jfma.2022.12.005_bib23","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (RITUX3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2022.12.005_bib24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jfma.2022.12.005_bib25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1365-2133.2011.10575.x","article-title":"British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011","volume":"165","author":"Meggitt","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dsi.2013.07.001","article-title":"Correlation of thiopurine methyltransferase and inosine triphosphate pyrophosphatase polymorphisms and adverse effects induced by azathioprine treatment in Taiwanese dermatology patients","volume":"32","author":"Wang","year":"2014","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.jfma.2022.12.005_bib28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2018.00460","article-title":"NUDT15 R139c variants increase the risk of azathioprine-induced leukopenia in Chinese autoimmune patients","volume":"9","author":"Fei","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jfma.2022.12.005_bib29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jfma.2019.04.020","article-title":"Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy","volume":"119","author":"Cho","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.12.005_bib30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid","volume":"161","author":"G\u00fcrcan","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2133.2011.10732.x","article-title":"Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris","volume":"166","author":"Behzad","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib33","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1111\/jdv.14144","article-title":"Fatal infection of pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab","volume":"31","author":"Wei","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfma.2022.12.005_bib34","doi-asserted-by":"crossref","DOI":"10.1684\/ejd.2018.3373","article-title":"Pneumocystis jirovecii pneumonia infection in pemphigus patients treated with rituximab: an observational nationwide epidemiological study in Taiwan","volume":"28","author":"Wei","year":"2018","journal-title":"Eur J Dermatol"},{"issue":"Suppl 4","key":"10.1016\/j.jfma.2022.12.005_bib35","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1111\/ajt.12119","article-title":"Pneumocystis pneumonia in solid organ transplantation","volume":"13","author":"Martin","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2022.12.005_bib36","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/archdermatol.2010.257","article-title":"Pemphigus and osteoporosis: a case-control study","volume":"146","author":"Wohl","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib37","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1365-4632.2006.02916.x","article-title":"Value of direct immunofluorescence in predicting remission in pemphigus vulgaris","volume":"45","author":"Balighi","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib38","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2015.10.051","article-title":"Immunologic prediction of relapse in patients with pemphigus vulgaris (pv) in clinical remission","volume":"74","author":"Daneshpazhooh","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2022.12.005_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17061983","article-title":"The risk of depression in patients with pemphigus: a nationwide cohort study in Taiwan","volume":"17","author":"Hsu","year":"2020","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.jfma.2022.12.005_bib40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1684\/ejd.2017.3060","article-title":"Comorbid autoimmune diseases in patients with pemphigus: a nationwide case-control study in Taiwan","volume":"27","author":"Chiu","year":"2017","journal-title":"Eur J Dermatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622004442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622004442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:50:36Z","timestamp":1760539836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664622004442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0929664622004442"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.12.005","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taiwanese dermatological association (TDA) consensus for the management of pemphigus","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}